Get The Free Sample Complete
SWOT & PESTLE Analysis Report
This report is shared in order to give you an idea of what the complete SWOT & PESTLE analysis report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals. We also guarantee that you cannot find matched quality at such competitive and economic pricing.
Get Your Free Summary Copy of the
SWOT & PESTLE Analysis Report
Get the summary SWOT & PESTLE.com report delivered straight to your email inbox for free.
Our insightful and holistic reports have helped corporate,academia and researchers to take their research forward. Like us on Facebook to stay updated with the latest published SWOT & PESTLE Report.

Merck SWOT and PESTLE Analysis

ID : 52433753| Jul 2018| 15 pages

COMPANY PROFILE -Merck

Business Sector :Pharmaceuticals and Chemicals

Operating Geography :Germany, Europe, Global

About Merck :

The Merck Group (commonly known as Merck) is one of the oldest multinational chemical and pharmaceutical company globally, founded in 1668 by Friedrich Jacob Merck. Entire business of the group can be broadly divided into three categories: Healthcare, Life Science and Performance Materials. Headquartered in Darmstadt, Germany, Merck operates in 66 countries with more than 50,000 employees as of 2018.

Merck Revenue :


€ 15,327 million – FY ended 31st December 2017 (year-on-year growth of 2%)
€ 15,024 million – FY ended 31st December 2016

Ownership / Major shareholders :

Merck family is the majority owner of the company and holds 70.3% of the shares as of 2018.

Competitive Analysis of Merck

SWOT
PESTLE
The SWOT Analysis for Merck is presented below:
Strengths
Weaknesses
1. Strong financial performance
2. Risk diversified business portfolio
3. Leading the performance material market
4. Focus on R&D and innovation through investments and partnerships
5. Strong Investment grade rating
1. Weak player in Latin America, middle east and Africa
2. Few new drugs in the final R&D stage
Opportunities
Threats
1. Great potential to dominate future automotive and lighting display market
2. Patent approval for CRISPR technology
3. Use synergies from Sigma-Aldrich acquisition
1. Changes in political landscape of Europe: Brexit and growing protectionism
2. Changes in U.S. or foreign laws and regulations
3. Adverse changes in U.S., global, regional or local economic conditions
SWOT & PESTLE (combined)
Complete Report
USD 12.53
*
Great quality, Affordable pricing.
Safe and secure payments

Detailed SWOT Analysis of Merck

Strength

1. Consistently strong financial performance: Merck has shown strong year-on-year growth in the revenue and profit in all the periods. In year 2016, group’s net sales grew by 17.0% to €15 billion. In the same year EBIDTA grew by 23.7% and reached €4.5 billion with a high profit margin of 29.9%. Earnings per share rose by 27.5% to €6.21 and free cash flow increased by 20.0% to €3.3 billion. The sales grew by 2% in FY17 to €15.3 billion and the EBIDTA for Merck stood at €4.4 billion in 2017 with an EPS of €6.16. The company has reduced its net debt by around € 1.4 billion in 2017 and is on track to reduce its debt level to below 2 again by end of 2018.

2. Risk diversified business portfolio: Merck has diversified its business in 3 different sectors: healthcare, life sciences and performance materials. From Prescription medicines to over the counter drugs, lab materials to biotech and creating chemicals and OLED materials used in production of displays and ICs, Merck serves different uncorrelated markets, this reduces the overall business risk.

3. Leading the performance material market: Merck’s Performance Materials business is leading the market in liquid crystals and photoresist materials, as well as they are one of the leading suppliers of organic light emitting diodes (OLED) materials, and decorative and functional effect pigments. Merck has more than 2,500 patents for liquid crystals and 1,400 patents for OLED technologies, this shows their market dominance in the segment. The company also opened a new applications laboratory in China in July 2017 through which it will provide comprehensive, customized services for quality performance material products. Further the company also opened a production facility for liquid crystal window modules in Veldhoven, Holland in November 2017, investing around € 15 million.

4. Focus on R&D and innovation through investments and partnerships: Merck invested €2 billion and €2.14 billion in R&D in year 2016 and 2017 respectively which translated to 13.2% and 14% of their total sales in respective years. Each year Merck’s healthcare business invests roughly around 20% of total sales to R&D activities aimed at discovering and developing new therapies. The company has also entered into an agreement with Vertex Pharmaceuticals for four promising R&D DNA damage response (DDR) programs. The collaboration with big data analytics firm Palantir in 2017, will help the company rapidly develop and deliver medicines. The European patent office also granted Merck a patent for its CRISPR technology which can be used in disease modelling and genomic integration method for eukaryotic cells. Merck has a total of 6800 employees working in R&D with hubs located in countries such as UK, Taiwan, South Korea, USA, Japan, Israel and several others.

5. Strong Investment grade rating: Ratings given by external agencies are an important indicator of a company’s creditworthiness and financial stability. Merck has a Baa1 rating from Moody’s and an A rating from S&P, both with a stable outlook. Rating given by European agency Scope is A- with a stable outlook. The ratings have been given for the year 2017.

Weakness

This section is available only in the 'Complete Report' on purchase.

Opportunity

This section is available only in the 'Complete Report' on purchase.

Threat

This section is available only in the 'Complete Report' on purchase.

Key Business Segments / Diversification :

Merck
Healthcare Life Science Performance Materials

Recent Acquisition / Mergers / Alliance / Joint Ventures / Divestitures :

Name
Business Segment
Year
Type
Objective/Synergy Achieved
Merck Consumer Health SegmentConsumer Health2018DivestmentThe divestment will help Merck Group to strategically focus on innovation-driven businesses within Healthcare, Life Science and Performance Materials.
BioControlLife Science2017AcquisitionThe acquisition was aimed to complements Merck's existing products in food pathogen testing and offer its customers complete workflow solutions in the segment
Source: Company website and other reliable sources. The detailed table is available in the Complete Report.
SWOT & PESTLE (combined)
Complete Report
USD 12.53
*
Great quality, Affordable pricing.
Safe and secure payments

Check out analysis of other relevant companies

TABLE OF CONTENTS
DELIVERY AND FORMAT
WHY CHOOSE US?
References used in Merck Analysis Report

1. Merck KGaA Annual Report 2016: https://www.merckgroup.com/content/dam/web/corporate/non-images/investors/reports-and-financials/annual-and-quarterly-reports/en/2016/AR_2016_EN.pdf
2. Innovation and R&D at Merck https://www.merckgroup.com/en/investors/why-invest/innovation.html https://www.merckgroup.com/en/research/our-approach-to-research-and-development/r-and-d-in-performance-materials.html
3. Sector and area wise financials of Merck https://www.merckgroup.com/en/investors/reports-and-financials/financials.html
4. Top patent losses in recent years http://www.gabionline.net/Generics/General/The-biggest-drug-patent-losses-for-2013

Copyrights and Disclaimer

The Merck Group SWOT and PESTLE analysis has been conducted by Sachin Mishra and reviewed by senior analysts from Barakaat Consulting.

Copyright of The Merck SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions and Disclaimer for usage guidelines.

Merck SWOT and PESTLE Analysis
Price : USD 12.53